Key result
This review summarizes the pharmacological properties and clinical trial outcomes of oral Factor Xa inhibitors for the prophylaxis and treatment of venous thromboembolism.
Why the study?
Do oral Factor Xa inhibitors provide effective prophylaxis and treatment for venous thromboembolism?
Do oral Factor Xa inhibitors provide effective prophylaxis and treatment for venous thromboembolism?
This review summarizes the pharmacological properties and clinical trial outcomes of oral Factor Xa inhibitors for the prophylaxis and treatment of venous thromboembolism.
May inform VTE management decisions with oral Factor Xa inhibitors; leaves open need for updated comparative trials in special populations.
The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and would potentially soon revolutionize coagulation medicine. The first part of this article reviews oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban and YM150--exploring the outcomes of major clinical trials for prophylaxis and treatment of venous thromboembolism--and also briefly outlining their pharmacological properties. The second part of the article (in a separate issue) will cover oral Factor IIa (thrombin), such as dabigatran and AZD0837 and oral Factor IX inhibitors, such as TTP889.
No takes yet. Share an insight, caveat, or question.
Rohtesh S. Mehta (2010) conducted a review in Venous thromboembolism. Oral Factor Xa inhibitors (rivaroxaban, apixaban, eribaxaban, edoxaban, YM150) was evaluated. This review summarizes the pharmacological properties and clinical trial outcomes of oral Factor Xa inhibitors for the prophylaxis and treatment of venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: